These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 28562282

  • 21. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment.
    Durongpisitkul K, Gururaj VJ, Park JM, Martin CF.
    Pediatrics; 1995 Dec; 96(6):1057-61. PubMed ID: 7491221
    [Abstract] [Full Text] [Related]

  • 22. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
    Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A, RAISE study group investigators.
    Lancet; 2012 Apr 28; 379(9826):1613-20. PubMed ID: 22405251
    [Abstract] [Full Text] [Related]

  • 23. Probable efficacy of high-dose salicylates in reducing coronary involvement in Kawasaki disease.
    Koren G, Rose V, Lavi S, Rowe R.
    JAMA; 1985 Aug 09; 254(6):767-9. PubMed ID: 4009911
    [Abstract] [Full Text] [Related]

  • 24. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
    J Med Assoc Thai; 2002 Nov 09; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [Abstract] [Full Text] [Related]

  • 25. Efficacy between low and high dose aspirin for the initial treatment of Kawasaki disease: Current evidence based on a meta-analysis.
    Zheng X, Yue P, Liu L, Tang C, Ma F, Zhang Y, Wang C, Duan H, Zhou K, Hua Y, Wu G, Li Y.
    PLoS One; 2019 Nov 09; 14(5):e0217274. PubMed ID: 31117119
    [Abstract] [Full Text] [Related]

  • 26. Preventing coronary artery abnormalities: a need for earlier diagnosis and treatment of Kawasaki disease.
    Dominguez SR, Anderson MS, El-Adawy M, Glodé MP.
    Pediatr Infect Dis J; 2012 Dec 09; 31(12):1217-20. PubMed ID: 22760536
    [Abstract] [Full Text] [Related]

  • 27. Duration of high-dose aspirin therapy does not affect long-term coronary artery outcomes in Kawasaki disease.
    Migally K, Braunlin EA, Zhang L, Binstadt BA.
    Pediatr Res; 2018 Jun 09; 83(6):1136-1145. PubMed ID: 29554081
    [Abstract] [Full Text] [Related]

  • 28. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose.
    Terai M, Shulman ST.
    J Pediatr; 1997 Dec 09; 131(6):888-93. PubMed ID: 9427895
    [Abstract] [Full Text] [Related]

  • 29. Guideline-Concordant Treatment of Kawasaki Disease With Immunoglobulin and Aspirin and the Incidence of Coronary Artery Aneurysm.
    Michihata N, Matsui H, Fushimi K, Yasunaga H.
    Clin Pediatr (Phila); 2015 Oct 09; 54(11):1076-80. PubMed ID: 25573948
    [Abstract] [Full Text] [Related]

  • 30. Kawasaki Disease - A Review of Treatment and Outcomes in an Irish Paediatric Cohort 2010-14.
    Flinn AM, Gavin PJ, McMahon CJ, Oslizok P, Butler KM.
    Ir Med J; 2018 Feb 09; 111(2):691. PubMed ID: 29952440
    [Abstract] [Full Text] [Related]

  • 31. Kawasaki disease: part II. Complications and treatment.
    Bayers S, Shulman ST, Paller AS.
    J Am Acad Dermatol; 2013 Oct 09; 69(4):513.e1-8; quiz 521-2. PubMed ID: 24034380
    [Abstract] [Full Text] [Related]

  • 32. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.
    Sundel RP, Baker AL, Fulton DR, Newburger JW.
    J Pediatr; 2003 Jun 09; 142(6):611-6. PubMed ID: 12838187
    [Abstract] [Full Text] [Related]

  • 33. [Kawasaki disease in children--9 years experience].
    Kowalczyk M, Kawalec W, Daszkowska-York J, Turska-Kmieć A, Brzezińska-Rajszys G, Sobielarska D, Ziółkowska L, Kościesza A, Jagiełłowicz D, Mirecka-Rola A.
    Med Wieku Rozwoj; 2005 Jun 09; 9(2):179-93. PubMed ID: 16085959
    [Abstract] [Full Text] [Related]

  • 34. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease.
    Berdej-Szczot E, Małecka-Tendera E, Gawlik T, Firek-Pędras M, Szydłowski L, Gawlik A.
    Kardiol Pol; 2017 Jun 09; 75(3):261-266. PubMed ID: 27995598
    [Abstract] [Full Text] [Related]

  • 35. High-dose aspirin for Kawasaki disease: outdated myth or effective aid?
    Amarilyo G, Koren Y, Brik Simon D, Bar-Meir M, Bahat H, Helou MH, Mendelson A, Hezkelo N, Chodick G, Berkun Y, Eisenstein E, Butbul Aviel Y, Barkai G, Bolkier Y, Padeh S, Brik R, Hashkes PJ, Harel L, Uziel Y.
    Clin Exp Rheumatol; 2017 Jun 09; 35 Suppl 103(1):209-212. PubMed ID: 28079513
    [Abstract] [Full Text] [Related]

  • 36. [Six Kawasaki disease patients with acute coronary artery thrombosis].
    Zhou SL, Luo JP, Qi YQ, Liang YG, Wang W, Gong FQ.
    Zhonghua Er Ke Za Zhi; 2013 Dec 09; 51(12):925-9. PubMed ID: 24495764
    [Abstract] [Full Text] [Related]

  • 37. [Risk stratification and prediction of resistance to intravenous immunoglobulin in Kawasaki disease].
    Kobayashi T, Inoue Y, Morikawa A.
    Nihon Rinsho; 2008 Feb 09; 66(2):332-7. PubMed ID: 18260333
    [Abstract] [Full Text] [Related]

  • 38. Kawasaki disease. Kawasaki disease?
    Moss KW.
    Alaska Med; 2000 Feb 09; 42(2):30-6. PubMed ID: 10916855
    [Abstract] [Full Text] [Related]

  • 39. Revisiting the role of steroids and aspirin in the management of acute Kawasaki disease.
    Dhanrajani A, Yeung RSM.
    Curr Opin Rheumatol; 2017 Sep 09; 29(5):547-552. PubMed ID: 28661936
    [Abstract] [Full Text] [Related]

  • 40. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb 09; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.